Value-Based Management of Dry Eye Disease: Clinical Insights, Economic Considerations, and Individualized Treatment Strategies

Alice T. Epitropoulos MD, FACS discusses the updated 2023 AAO dry eye disease (DED) guidelines, emphasizing their impact on treatment selection, formulary management, and the importance of aligning therapies with underlying pathophysiology. She also addresses ongoing challenges such as diagnostic coding limitations and step therapy practices that may not reflect patient needs.

Episodes

EP. 1: DED in Clinical Practice

Dr Epitropoulos discusses how recent breakthroughs have shaped the clinical approach to DED and examines the impact that ocular surface inflammation has on patient care.

EP. 2: Treating the Subtypes of DED

Dr Epitropoulos reviews aqueous-deficient dry eye (ADDE), evaporative dry eye (EDE), and mixed-type DED, highlighting how treatment strategies vary across these subtypes.

EP. 3: Clinical Guidelines and Approaches to DED Therapy

Dr Epitropoulos highlights AAO guideline updates as well as the role of in-office patient education in the DED treatment strategy.

EP. 4: Personalized Treatment Selection in DED

Dr Epitropoulos considers treatment switching and step therapy policies when individualizing care for patients with DED.